Background: Extended-Spectrum β-Lactamases (ESBLs) producing bacteria are increasing in number and causing more severe infections because of their continuous mutation and multidrug resistance property which make its treatment difficult. Thus reliable, sensitive and low cost method to detect ESBLs producers, therefore, is of major interest. 
INTRODUCTION
Extended-Spectrum β-Lactamases (ESBLs) producing bacteria are becoming a major threat for patients in the hospital, long-term care facilities and community. Inappropriate antibiotic selection in infections caused by these organisms is associated with treatment failures, poor clinical outcomes, increased mortality and longer hospital stays 1 .
Extended-Spectrum β-Lactamases producing bacteria produce Extended-Spectrum β-Lactamase (ESBL) enzymes that mediate resistance to extended spectrum (Third generation) cephalosporins (e.g. Ceftazidime, cefotaxime, ceftrixone etc.) and monobactams (e.g. Aztreonam) but do not affect cephamycins (e.g. Cefoxitin and cefotatan) or carbapenems (e.g. meropenem or imipenem) and are inhibited by β-Lactamase inhibitors such as clavulanate, sulbactam and tazobactam 2, 3, 4 . ESBLs have been found in a wide range of gram-negative rods. Klebsiella pneumoniae seems to remain the major ESBLs producer. Another very important organism is Nura Nasrin Rowshan Ara 6 Escherichia coli 2 . Other organisms reported to harbour ESBLs include Enterobacter species, Salmonella species, Morganella morganii, Proteus mirabilis, Serratia marcescens and Pseudomonas aeruginosa 4, 5, 6 . ESBLs have spread threateningly in many regions of the world and they presently comprise over 300 variants. The widespread use of the third generation cephalosporins and aztreonam is believed to be the major cause of the mutations in these enzymes, which has led to the emergence of the ESBLs 1 .
ESBL-mediated resistance is not always detectable in routine susceptibility tests. The inability of the clinical laboratory to accurately detect and report ESBLs has resulted in avoidable therapeutic failures in patients, and outbreaks of multi-drug resistant gram-negative bacterial pathogens. This study was undertaken to compare the sensitivity between double disc synergy test & phenotypic confirmatory test to detect ESBLs producing bacteria. 
MATERIALS AND METHODS

This
Laboratory Procedure
After collecting samples under all aseptic precautions, wound swabs & pus were inoculated in Blood agar and MacConkey agar media and urine samples were inoculated in Cystine Lactose Electrolyte Deficient (CLED) agar media by calibrated wire loop (0.01ml). Identification of organisms were done as per standard laboratory methods of identification. Screening for ESBL producers by dilution method Agar dilution method: The screening for ESBL producers was done by agar dilution method as was recommended by Clinical Laboratories Standard Institute (CLSI). Any of the isolated organisms found to be grown at this stated screening antibiotics concentration (That is, MIC of the ceftriaxone, ceftazidime and cefotaxime >2µg/ml) according to CLSI, 2007 was considered as possible ESBL producers and spelled for the confirmatory tests. The use of more than one antimicrobial agent for screening improves the sensitivity of detection 8 .
Detection of ESBLs by the confirmatory tests Phenotypic confirmatory test:
Confirmation of the ESBL producing isolates was done by the phenotypic confirmatory test according to CLSI recommendation. In this test, third generation cephalosporin i.e. ceftazidime (30 µg) and cefotaxime (30 µg) disc alone and in combination with clavulanic acid (10 µg) were used. Ceftazidime, cefotaxime discs were placed on one side and ceftazidime, cefotaxime discs combined with clavulanic acid (30/10 µg) were placed on other side of the inoculated plate. After overnight incubation at 37 o C, diameter of zone of inhibition was measured. A 5 mm or more increases in diameter of zone of inhibition for ceftazidime and cefotaxime tested in combination with clavulanic acid versus its zone when ceftazidime and cefotaxime tested alone confirms an ESBLs producing organism 8 .
Double disc synergy test/disc approximation method
By this method, synergy between a disc of augmentin (Amoxycillin and clavulanic acid) and third generation cephalosporins was detected. The clavulanate in augmentin disc diffuses through the agar and inhibits the -lactamases surrounding third generation cephalosporin disc. Discs containing 30µg of ceftazidime, cefotaxime and ceftriaxone were placed over inoculated Mueller-Hinton agar plates 20 mm apart from centrally placed amoxicillin-clavulanic acid disc (20/10 µg). Following overnight incubation at 37°C, diameter of zone of inhibition was measured. Extension of the edge of the inhibition zone of ceftazidime, cefotaxime and ceftriaxone disc on the side exposed to the disc containing amoxicillinclavulanic acid was positive for ESBL 9 . It appears total 150 isolated gram-negative bacteria were screened for suspected ESBLs producers on the basis of MIC ESBL breakpoints, out of which 142 (94.67%) were found suspected ESBLs producers & 8 (5.33%) gave negative result (Figure-3 ). 
Comparison between Phenotypic Confirmatory Test & Double Disc Synergy Test
DISCUSSION
In the present study, a total of 235 samples were collected and of which 115 were wound swab & pus, and 120 were urine samples. From these samples, culture positive bacterial isolates were 176(74.89%) and among which 105(91.30%) from wound swab & pus, and 71(59.17%) from urine samples. This result is closely related to that of Rahman in Bangabandhu Sheikh Mujib Medical University (BSMMU) Dhaka, who found 69.41% culture positive isolates and isolated 93.92% organisms were from wound swab & pus, and 53.57% from urine samples 10 .
Among the bacterial isolates, 150(85.23%) were gram-negative and 26(14.77%) were gram-positive in our study ( 10, 11 . These sorts of variation are not unexpected, because it depends upon some external factors like socioeconomic conditions, hygienic status, environmental factors, level of education, and genetic factors 12 .
In the present study, we found 142(94.67%) suspected ESBLs producers from 150 gram-negative isolates, based on Minimum Inhibitory Concentration (MIC) ESBLs screening breakpoints ( Figure 3 ). As using more than one antibiotic increase the sensitivity, we used three third generation cephalosporins (Ceftriaxone, ceftazidime & cefotaxime) for the screening 8 .
Our finding is closely related to that of Metri et al in North Karnataka, India, who found 91.74% suspected ESBLs producers by screening test. 
74(52.11%) by Double Disc Synergy Test (DDST).
When these 142 screening positive isolates were subjected to the confirmatory tests, 74(52.11%) were confirmed as ESBL producers by Double Disc Synergy Test (DDST) (Figure 4 ) and 89(62.68%) by Phenotypic Confirmatory Test (PCT) ( Figure 5 ). Closely similar to the present study, Dalela (2012) 14 . Of the two tests, used in the study, phenotypic confirmatory test found to be more sensitive procedure than double disc synergy test for the detection of ESBLs producing organisms. Similar findings were also reported by some other studies 1, 16, 17, 18 . For this reason, some authors recommended phenotypic confirmatory test for the detection of ESBLs producers 14, 18, 19 .
CONCLUSION
Existing of extended spectrum -lactameses in bacteria and their potential multidrug resistance will create serious problem in the future as their continuous mutation and limited therapeutic option. Indiscriminate use of antibiotics especially 3 rd generation cephalosporins and monobactams should be avoided. The regular detection of ESBLs producing organisms by conventional methods should be carried out in every laboratory where molecular methods cannot be performed.
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